Japan the first market for Eisai/Toyama's new arthritis option iguratimod
This article was originally published in Scrip
Executive Summary
Eisai and Toyama Chemical have launched the oral disease-modifying antirheumatic drug (DMARD) iguratimod in Japan, its first market worldwide, as Careram and Kolbet respectively, for the treatment of rheumatoid arthritis.